EGFR Signaling in Cancer (2nd Edition)

Dear Colleagues,

The epidermal growth factor receptor (EGFR) pathway plays important roles in many cellular processes, including cell growth, differentiation, motility, inflammation, and stem cell biology. The overexpression or mutation of EGFR is associated with the development of various types of cancers, such as breast cancer, lung cancer, glioblastoma, and colorectal cancer. The EGFR pathway regulates tumorigenesis and metastasis through its downstream PI3K/AKT, MEK/ERK, and JAK/STAT signaling. It also regulates the interactions between tumor cells and the surrounding tumor microenvironment. As a result, the EGFR pathway represents an attractive therapeutic target for cancer treatment. Clinical trials of EGFR-targeted therapy with monoclonal antibodies or tyrosine kinase inhibitors have shown efficacy in some cancer types (e.g., lung and colorectal cancers, as well as inflammatory breast cancer). Still, EGFR-targeted therapy is not very effective in other cancer types, and some patients develop drug resistance. It is critical to elucidate the biological function of the EGFR pathway in regulating tumor cells as well as the tumor microenvironment and establish more effective combination therapies with anti-EGFR agents.

This Special Issue will highlight novel findings on different aspects of the EGFR pathway, including, but not limited to, (1) the function of the EGFR signaling pathway in tumors and the tumor microenvironment in different cancer types; (2) the mechanism of resistance to EGFR-targeted therapy and approaches to overcoming this resistance; (3) the development of drugs targeting EGFR and EGFR signaling; and (4) clinical trials of EGFR-targeted therapy in different cancer types. We hope that this Special Issue will advance our understanding of the EGFR pathway in tumor progression, leading to improved treatments and prolonged survival for cancer patients.

Dr. Xiaoping Wang
Prof. Dr. Naoto T. Ueno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• epidermal growth factor receptor (EGFR)
• tumor microenvironment
• drug resistance
• clinical trial
• cell signaling

• EGFR Signaling in Cancer in Cancers (7 articles)